相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
Diego Chowell et al.
SCIENCE (2018)
Relationship between UGT1A1*27 and UGT1A1*7 polymorphisms and irinotecan-related toxicities in patients with lung cancer
Minoru Fukuda et al.
THORACIC CANCER (2018)
Pathogenic Germline Variants in 10,389 Adult Cancers
Kuan-lin Huang et al.
CELL (2018)
Patients' Views of Treatment-Focused Genetic Testing (TFGT): Some Lessons for the Mainstreaming of BRCA1 and BRCA2 Testing
Sarah Wright et al.
JOURNAL OF GENETIC COUNSELING (2018)
The landscape of genomic alterations across childhood cancers
Susanne N. Groebner et al.
NATURE (2018)
Seminal Cell Free DNA Concentration Levels Discriminate Between Prostate Cancer and Benign Prostatic Hyperplasia
Giovanni Ponti et al.
ANTICANCER RESEARCH (2018)
Cancer Molecular Screening and Therapeutics (MoST): a framework for multiple, parallel signal-seeking studies of targeted therapies for rare and neglected cancers
Subotheni Thavaneswaran et al.
MEDICAL JOURNAL OF AUSTRALIA (2018)
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Jennifer K. Litton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation
Rachna T. Shroff et al.
JCO PRECISION ONCOLOGY (2018)
Assigning clinical meaning to somatic and germ-line whole-exome sequencing data in a prospective cancer precision medicine study
Arezou A. Ghazani et al.
GENETICS IN MEDICINE (2017)
Mainstreaming cancer genetics: A model integrating germline BRCA testing into routine ovarian cancer clinics
Maira Kentwell et al.
GYNECOLOGIC ONCOLOGY (2017)
Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing
Diana Mandelker et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Basket Trials in Oncology: A Trade-Off Between Complexity and Efficiency
Kristen M. Cunanan et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication
Steven Lemery et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
DNA Damage and Repair Biomarkers of Immunotherapy Response
Kent W. Mouw et al.
CANCER DISCOVERY (2017)
POLE and POLD1 screening in 155 patients with multiple polyps and early-onset colorectal cancer
Clara Esteban-Jurado et al.
ONCOTARGET (2017)
Lung Cancer: Understanding its Molecular Pathology and the 2015 WHO Classification
Kentaro Inamura
FRONTIERS IN ONCOLOGY (2017)
MET in human cancer: germline and somatic mutations
Elizabeth A. Tovar et al.
ANNALS OF TRANSLATIONAL MEDICINE (2017)
The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer
Mark M. Pomerantz et al.
CANCER (2017)
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity
Matthew T. Chang et al.
NATURE BIOTECHNOLOGY (2016)
PARP inhibitor receives FDA breakthrough therapy designation in castration resistant prostate cancer: beyond germline BRCA mutations
T. Helleday
ANNALS OF ONCOLOGY (2016)
Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol
F. Meric-Bernstam et al.
ANNALS OF ONCOLOGY (2016)
How I treat MDS and AML in Fanconi anemia
Regis Peffault de Latour et al.
BLOOD (2016)
Neurofibromatosis type 1 associated low grade gliomas: A comparison with sporadic low grade gliomas
Jelte Helfferich et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer
Janice M. Mehnert et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency
Eric Bouffet et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair
Miguel A. Villalona-Calero et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Germline Mutations in Predisposition Genes in Pediatric Cancer
Abdenasser Bardai et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas
Eva Dombi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
M. R. Mirza et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Should CYP2D6 be genotyped when treating with tamoxifen?
Marzia Del Re et al.
PHARMACOGENOMICS (2016)
Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy
Tanner M. Johanns et al.
CANCER DISCOVERY (2016)
Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair
Miguel A. Villalona-Calero et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid Tumors
D. Williams Parsons et al.
JAMA ONCOLOGY (2016)
Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA
Kasmintan A. Schrader et al.
JAMA ONCOLOGY (2016)
Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms AMeta-analysis
Maria Schwaederle et al.
JAMA ONCOLOGY (2016)
Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors
Tadas K. Rimkus et al.
CANCERS (2016)
Defining actionable mutations for oncology therapeutic development
T. Hedley Carr et al.
NATURE REVIEWS CANCER (2016)
Cytotoxic and targeted therapy for hereditary cancers
Aglaya G. Iyevleva et al.
HEREDITARY CANCER IN CLINICAL PRACTICE (2016)
High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation
Tatiana V. Gorodnova et al.
CANCER LETTERS (2015)
The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012)
Andrew Tutt et al.
CANCER RESEARCH (2015)
Response to everolimus is seen in TSC-associated SEGAs and angiomyolipomas independent of mutation type and site in TSC1 and TSC2
David J. Kwiatkowski et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2015)
Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology
Sue Richards et al.
GENETICS IN MEDICINE (2015)
Familial and Multiple Gastrointestinal Stromal Tumors with Fair Response to a Half-dose of Imatinib
Shigeki Bamba et al.
INTERNAL MEDICINE (2015)
Molecular Profiling and Targeted Therapy for Advanced Thoracic Malignancies: A Biomarker-Derived, Multiarm, Multihistology Phase II Basket Trial
Ariel Lopez-Chavez et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032
Giles W. Robinson et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Bella Kaufman et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial
Nicole Basset-Seguin et al.
LANCET ONCOLOGY (2015)
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial
Christophe Le Tourneau et al.
LANCET ONCOLOGY (2015)
Association of CDK4 germline and BRAF somatic mutations in a patient with multiple primary melanomas and BRAF inhibitor resistance
Maurizio Governa et al.
MELANOMA RESEARCH (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
David M. Hyman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
J. Mateo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Genetic Variation as a Modifier of Association Between Therapeutic Exposure and Subsequent Malignant Neoplasms in Cancer Survivors
Smita Bhatia
CANCER (2015)
Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients
T. Byrski et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
RET Gene Mutations (Genotype and Phenotype) of Multiple Endocrine Neoplasia Type 2 and Familial Medullary Thyroid Carcinoma
Geoffrey W. Krampitz et al.
CANCER (2014)
Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothened Inhibition
Marcel Kool et al.
CANCER CELL (2014)
ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in Neuroblastoma
Scott C. Bresler et al.
CANCER CELL (2014)
Nucleotide excision repair: Why is it not used to predict response to platinum-based chemotherapy?
Nikola A. Bowden
CANCER LETTERS (2014)
Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas
Kathryn P. Pennington et al.
CLINICAL CANCER RESEARCH (2014)
SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma
Julien Hadoux et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Open-Label, Exploratory Phase II Trial of Oral Itraconazole for the Treatment of Basal Cell Carcinoma
Daniel J. Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Germline Mutations in SUFU Cause Gorlin Syndrome-Associated Childhood Medulloblastoma and Redefine the Risk Associated With PTCH1 Mutations
Miriam J. Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium 'Care for CMMRD' (C4CMMRD)
Katharina Wimmer et al.
JOURNAL OF MEDICAL GENETICS (2014)
Molecular Analysis for Therapy Choice: NCI MATCHd
Barbara A. Conley et al.
SEMINARS IN ONCOLOGY (2014)
Vandetanib in Children and Adolescents with Multiple Endocrine Neoplasia Type 2B Associated Medullary Thyroid Carcinoma
Elizabeth Fox et al.
CLINICAL CANCER RESEARCH (2013)
Phase I Study of Vismodegib in Children with Recurrent or Refractory Medulloblastoma: A Pediatric Brain Tumor Consortium Study
Amar Gajjar et al.
CLINICAL CANCER RESEARCH (2013)
Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Cabozantinib in Progressive Medullary Thyroid Cancer
Rossella Elisei et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
New Developments in Thyroid Cancer
Robert I. Haddad
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2013)
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial
David Neal Franz et al.
LANCET (2013)
Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial
John J. Bissler et al.
LANCET (2013)
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
Shahneen K. Sandhu et al.
LANCET ONCOLOGY (2013)
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study
Yael P. Mosse et al.
LANCET ONCOLOGY (2013)
Implementing personalized cancer genomics in clinical trials
Richard Simon et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
Clinically relevant fatigue in recurrence-free prostate cancer survivors
D. J. Storey et al.
ANNALS OF ONCOLOGY (2012)
BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation-Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
Kathryn Alsop et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
Samuel A. Wells et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
D. Ross Camidge et al.
LANCET ONCOLOGY (2012)
Inhibiting the Hedgehog Pathway in Patients with the Basal-Cell Nevus Syndrome
Jean Y. Tang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer
Tomasz Byrski et al.
BREAST CANCER RESEARCH (2012)
Inherited gastrointestinal stromal tumor syndromes: mutations, clinical features, and therapeutic implications
Michael A. Postow et al.
CLINICAL SARCOMA RESEARCH (2012)
Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients
P. M. L. H. Vencken et al.
ANNALS OF ONCOLOGY (2011)
Activating mutation in MET oncogene in familial colorectal cancer
Deborah W. Neklason et al.
BMC CANCER (2011)
von Hippel-Lindau disease: A clinical and scientific review
Eamonn R. Maher et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2011)
Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas
Barbara Norquist et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma
Georgina V. Long et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial
John Burn et al.
LANCET (2011)
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
Karen A. Gelmon et al.
LANCET ONCOLOGY (2011)
Itraconazole, a Commonly Used Antifungal that Inhibits Hedgehog Pathway Activity and Cancer Growth
James Kim et al.
CANCER CELL (2010)
Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality
Susan M. Domchek et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Andrew Tutt et al.
LANCET (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
M. William Audeh et al.
LANCET (2010)
Ethnic Differences and Functional Analysis of MET Mutations in Lung Cancer
Soundararajan Krishnaswamy et al.
CLINICAL CANCER RESEARCH (2009)
O-6-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine Tumors
Matthew H. Kulke et al.
CLINICAL CANCER RESEARCH (2009)
Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen
Werner Schroth et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Oral rapamycin reduces tumour burden and vascularization in Lkb1+/- mice
James Robinson et al.
JOURNAL OF PATHOLOGY (2009)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas
Keiran S. M. Smalley et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Oncogenic mutations of ALK kinase in neuroblastoma
Yuyan Chen et al.
NATURE (2008)
Rapamycin treatment for a child with germline PTEN mutation
Deborah J. Marsh et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2008)
Basal cell carcinomas: attack of the hedgehog
Ervin H. Epstein
NATURE REVIEWS CANCER (2008)
Effect of sunitinib on metastatic gastrointestinal stromal tumor in patients with neurofibromatosis type 1: A case report
M. Emin Kalender et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2007)
Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer)
H. F. A. Vasen et al.
JOURNAL OF MEDICAL GENETICS (2007)
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
George D. Demetri et al.
LANCET (2006)
Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition
Nuala McCabe et al.
CANCER RESEARCH (2006)
Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer
R. Jover et al.
GUT (2006)
KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs)
Jerzy Lasota et al.
SEMINARS IN DIAGNOSTIC PATHOLOGY (2006)
Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR
DW Bell et al.
NATURE GENETICS (2005)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
mTOR, translational control and human disease
AR Tee et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2005)
Hereditary cancer predisposition syndromes
JE Garber et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer
WHDN Cappel et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Tumour-infiltrating lymphocytes in colorectal cancer with microsatellite instability are activated and cytotoxic
SM Phillips et al.
BRITISH JOURNAL OF SURGERY (2004)
Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers:: The PROSE study group
TR Rebbeck et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer
E Marcuello et al.
BRITISH JOURNAL OF CANCER (2004)
PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor
A Chompret et al.
GASTROENTEROLOGY (2004)
Colorectal cancers with microsatellite instability display mRNA expression signatures characteristic of increased immunogenicity
Ayan Banerjea et al.
MOLECULAR CANCER (2004)
Gain-of-function mutations of platelet-derived growth factor receptor α gene in gastrointestinal stromal tumors
S Hirota et al.
GASTROENTEROLOGY (2003)
A novel germline mutation in the MET extracellular domain in a Korean patient with the diffuse type of familial gastric cancer -: art. no. e97
IJ Kim et al.
JOURNAL OF MEDICAL GENETICS (2003)
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
JC Yang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
GD Demetri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
ND Kauff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Environmental and heritable factors in the causation of cancer - Analyses of cohorts of twins from Sweden, Denmark, and Finland.
P Lichtenstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
分享论文
